NovoCure (NVCR) Other Non-Current Liabilities (2014 - 2025)

NovoCure has disclosed Other Non-Current Liabilities across 12 years of filings, most recently posting $19000.0 for Q3 2025.

• Other Non-Current Liabilities for Q3 2025 came in at $19000.0, up 5.56% year-over-year; the trailing twelve-month figure through Sep 2025 was $19000.0 (up 5.56% YoY), and the FY2024 annual result was $18000.0, changed 0.0% from the prior year.
• Other Non-Current Liabilities came in at $19000.0 for Q3 2025 at NovoCure, up from $18000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $379000.0 in Q3 2021 to a low of $18000.0 in Q4 2023.
• The 5-year median for Other Non-Current Liabilities is $119000.0 (2023), against an average of $112368.4.
• Across the five-year window, Other Non-Current Liabilities surged 125.6% in 2021 and tumbled 87.84% in 2023, its largest moves.
• NovoCure's Other Non-Current Liabilities stood at $166000.0 in 2021, then dropped by 10.84% to $148000.0 in 2022, then sank by 87.84% to $18000.0 in 2023, then changed by 0.0% to $18000.0 in 2024, then grew by 5.56% to $19000.0 in 2025.
• The last three Other Non-Current Liabilities figures came in at $19000.0 (Q3 2025), $18000.0 (Q2 2025), and $18000.0 (Q1 2025), per Business Quant data.